Intuitive Surgical Reports Strong Q1 2026 Earnings Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy ISRG?
Source: seekingalpha
- Significant Revenue Growth: Intuitive Surgical reported a 23% increase in Q1 revenue to $2.77 billion, with recurring revenue also rising by 23% to account for 86% of total revenue, indicating strong demand and customer loyalty in the surgical robotics market.
- Procedure Volume Increase: da Vinci procedures grew by 16% to 847,000, while Ion procedures surged by 39% to 43,000, demonstrating the expanding market acceptance and clinical application of the company's products.
- System Deployment Update: The company placed 431 da Vinci systems in Q1, including 232 da Vinci 5 systems, showcasing proactive progress in new product promotion and laying the groundwork for future market expansion.
- Optimistic Outlook: The company raised its full-year da Vinci procedure growth forecast to a range of 13.5% to 15.5%, and expects non-GAAP gross margins to be between 67.5% and 68.5%, reflecting confidence in future performance and positive market feedback.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 465.600
Low
575.00
Averages
637.32
High
740.00
Current: 465.600
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ISRG Q1 2026 Earnings Transcript
See More
INTUITIVE SURGICAL INC: PIPER SANDLER LOWERS TARGET PRICE FROM $620 TO $580
- Price Adjustment: Intuitive Surgical has reduced the price of its da Vinci surgical system's stock from $620 to $580.
- Market Impact: This price cut may influence market dynamics and accessibility for healthcare providers considering the purchase of the surgical system.
See More
Intuitive Surgical Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Intuitive Surgical reported a 23% increase in Q1 revenue to $2.77 billion, with recurring revenue also rising by 23% to account for 86% of total revenue, indicating strong demand and customer loyalty in the surgical robotics market.
- Procedure Volume Increase: da Vinci procedures grew by 16% to 847,000, while Ion procedures surged by 39% to 43,000, demonstrating the expanding market acceptance and clinical application of the company's products.
- System Deployment Update: The company placed 431 da Vinci systems in Q1, including 232 da Vinci 5 systems, showcasing proactive progress in new product promotion and laying the groundwork for future market expansion.
- Optimistic Outlook: The company raised its full-year da Vinci procedure growth forecast to a range of 13.5% to 15.5%, and expects non-GAAP gross margins to be between 67.5% and 68.5%, reflecting confidence in future performance and positive market feedback.
See More
Intuitive Surgical Q1 Earnings Exceed Expectations
- Earnings Beat: Intuitive Surgical reported a Q1 non-GAAP EPS of $2.50, surpassing expectations by $0.39, indicating robust profitability in the robotic surgery sector.
- Significant Revenue Growth: The company achieved Q1 revenue of $2.77 billion, a 23.1% year-over-year increase, exceeding forecasts by $150 million, demonstrating sustained strong performance in market demand and product sales.
- Optimistic Market Outlook: Despite an FDA warning regarding a medical device issue, Intuitive Surgical remains a leader in robotic surgery, with expectations for continued strong growth, further solidifying its market position.
- Increased Investor Confidence: Analysts maintain an optimistic view on the company's long-term growth potential, suggesting a hold despite elevated current valuations, reflecting market confidence in its future performance.
See More
Intuitive Reports Strong Q1 Results with 23% Revenue Growth
- Significant Revenue Growth: In Q1 2026, Intuitive reported revenue of $2.77 billion, a 23% increase year-over-year, primarily driven by increased procedure volumes and higher sales of da Vinci systems, indicating strong market demand in minimally invasive surgery.
- Increased System Deployments: The company placed 431 da Vinci surgical systems in Q1, a 17% increase from 367 in the same quarter of 2025, with 232 being da Vinci 5 systems, reflecting strong customer acceptance of new technologies.
- Profitability Improvement: Q1 GAAP net income reached $822 million, with diluted earnings per share of $2.28, significantly up from $698 million and $1.92 in Q1 2025, demonstrating ongoing enhancements in the company's profitability.
- Stock Buyback Program: The company repurchased 2.3 million shares of common stock for $1.1 billion in Q1, showcasing confidence in future growth while also enhancing earnings per share.
See More
Market Volatility and Corporate Earnings Updates
- Oil Price Surge Impact: The U.S. WTI crude oil price jumped 5% to $94 per barrel, causing the benchmark 10-Year Treasury yield to rise to 4.3%, leading to a market pullback after early gains, indicating investor sensitivity to oil price fluctuations.
- Mixed Earnings Reactions: While many companies exceeded analyst EPS expectations, such as UnitedHealth beating by 66 cents, most only slightly raised their full-year outlooks, reflecting management's cautious stance amid economic uncertainty.
- Ongoing Geopolitical Effects: Vice President JD Vance's diplomatic trip was postponed due to Iran's lack of response to U.S. negotiating positions, and despite a calming of geopolitical tensions, the market remains uneasy about the future of the Iran war ceasefire, impacting investor confidence.
- Upcoming Earnings Focus: Capital One is expected to report total revenue of $15.36 billion and adjusted EPS of $4.55, with investors looking for more meaningful synergies from the Discover acquisition, highlighting concerns about future growth prospects.
See More
ISRG Q1 2026 Earnings Transcript
See More
INTUITIVE SURGICAL INC: PIPER SANDLER LOWERS TARGET PRICE FROM $620 TO $580
- Price Adjustment: Intuitive Surgical has reduced the price of its da Vinci surgical system's stock from $620 to $580.
- Market Impact: This price cut may influence market dynamics and accessibility for healthcare providers considering the purchase of the surgical system.
See More
Intuitive Surgical Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Intuitive Surgical reported a 23% increase in Q1 revenue to $2.77 billion, with recurring revenue also rising by 23% to account for 86% of total revenue, indicating strong demand and customer loyalty in the surgical robotics market.
- Procedure Volume Increase: da Vinci procedures grew by 16% to 847,000, while Ion procedures surged by 39% to 43,000, demonstrating the expanding market acceptance and clinical application of the company's products.
- System Deployment Update: The company placed 431 da Vinci systems in Q1, including 232 da Vinci 5 systems, showcasing proactive progress in new product promotion and laying the groundwork for future market expansion.
- Optimistic Outlook: The company raised its full-year da Vinci procedure growth forecast to a range of 13.5% to 15.5%, and expects non-GAAP gross margins to be between 67.5% and 68.5%, reflecting confidence in future performance and positive market feedback.
See More
Intuitive Surgical Q1 Earnings Exceed Expectations
- Earnings Beat: Intuitive Surgical reported a Q1 non-GAAP EPS of $2.50, surpassing expectations by $0.39, indicating robust profitability in the robotic surgery sector.
- Significant Revenue Growth: The company achieved Q1 revenue of $2.77 billion, a 23.1% year-over-year increase, exceeding forecasts by $150 million, demonstrating sustained strong performance in market demand and product sales.
- Optimistic Market Outlook: Despite an FDA warning regarding a medical device issue, Intuitive Surgical remains a leader in robotic surgery, with expectations for continued strong growth, further solidifying its market position.
- Increased Investor Confidence: Analysts maintain an optimistic view on the company's long-term growth potential, suggesting a hold despite elevated current valuations, reflecting market confidence in its future performance.
See More
Intuitive Reports Strong Q1 Results with 23% Revenue Growth
- Significant Revenue Growth: In Q1 2026, Intuitive reported revenue of $2.77 billion, a 23% increase year-over-year, primarily driven by increased procedure volumes and higher sales of da Vinci systems, indicating strong market demand in minimally invasive surgery.
- Increased System Deployments: The company placed 431 da Vinci surgical systems in Q1, a 17% increase from 367 in the same quarter of 2025, with 232 being da Vinci 5 systems, reflecting strong customer acceptance of new technologies.
- Profitability Improvement: Q1 GAAP net income reached $822 million, with diluted earnings per share of $2.28, significantly up from $698 million and $1.92 in Q1 2025, demonstrating ongoing enhancements in the company's profitability.
- Stock Buyback Program: The company repurchased 2.3 million shares of common stock for $1.1 billion in Q1, showcasing confidence in future growth while also enhancing earnings per share.
See More
Market Volatility and Corporate Earnings Updates
- Oil Price Surge Impact: The U.S. WTI crude oil price jumped 5% to $94 per barrel, causing the benchmark 10-Year Treasury yield to rise to 4.3%, leading to a market pullback after early gains, indicating investor sensitivity to oil price fluctuations.
- Mixed Earnings Reactions: While many companies exceeded analyst EPS expectations, such as UnitedHealth beating by 66 cents, most only slightly raised their full-year outlooks, reflecting management's cautious stance amid economic uncertainty.
- Ongoing Geopolitical Effects: Vice President JD Vance's diplomatic trip was postponed due to Iran's lack of response to U.S. negotiating positions, and despite a calming of geopolitical tensions, the market remains uneasy about the future of the Iran war ceasefire, impacting investor confidence.
- Upcoming Earnings Focus: Capital One is expected to report total revenue of $15.36 billion and adjusted EPS of $4.55, with investors looking for more meaningful synergies from the Discover acquisition, highlighting concerns about future growth prospects.
See More
